Nerandomilast

Nerandomilast
Clinical data
Trade names	Jascayd
Other names	BI-1015550
AHFS/Drugs.com	Jascayd
License data	US DailyMed: Nerandomilast ;
Drug class	Phosphodiesterase-4 inhibitor
ATC code	None;
Legal status
Legal status	US: ℞-only ;
Identifiers
CAS Number	1423719-30-5 ;
PubChem CID	166177189 ;
DrugBank	DB18237 ;
ChemSpider	129160248 ;
UNII	I5DGT51IB8 ;
KEGG	D12975 ;
Chemical and physical data
Formula	C20H25ClN6O2S
Molar mass	448.97 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES C1CC(C1)(CO)NC2=NC(=NC3=C2[S@](=O)CC3)N4CCC(CC4)C5=NC=C(C=N5)Cl;
	InChI InChI=1S/C20H25ClN6O2S/c21-14-10-22-17(23-11-14)13-2-7-27(8-3-13)19-24-15-4-9-30(29)16(15)18(25-19)26-20(12-28)5-1-6-20/h10-11,13,28H,1-9,12H2,(H,24,25,26)/t30-/m1/s1; Key:UHYCLWAANUGUMN-SSEXGKCCSA-N;

Last updated October 30, 2025

Nerandomilast, sold under the brand name Jascayd, is a medication used for the treatment of idiopathic pulmonary fibrosis.^[1] It is a phosphodiesterase 4 (PDE4) inhibitor.^[1] It is taken by mouth.^[1]

Medical uses

Nerandomilast is indicated for the treatment of idiopathic pulmonary fibrosis in adults.^[1]

Society and culture

Legal status

Nerandomilast was approved for medical use in the United States in October 2025.^[1]^[2]

Names

Nerandomilast is the international nonproprietary name.^[3]

Nerandomilast is sold under the brand name Jascayd.^[1]

References

1 2 3 4 5 6 7 8 "Jascayd (nerandomilast tablets), for oral use" (PDF). Boehringer Ingelheim Pharmaceuticals, Inc. U.S. Food and Drug Administration.
↑ "U.S. FDA approves Boehringer's Jascayd (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade". Boehringer Ingelheim (Press release). Retrieved 9 October 2025.
↑ World Health Organization (2024). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 91". WHO Drug Information. 38 (1). hdl: 10665/378096 .

External links

Clinical trial number NCT05321069 for "A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)" at ClinicalTrials.gov
Clinical trial number NCT04419506 for "A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)" at ClinicalTrials.gov

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[Jascayd_FDA_label-1] 1 2 3 4 5 6 7 8 "Jascayd (nerandomilast tablets), for oral use" (PDF). Boehringer Ingelheim Pharmaceuticals, Inc. U.S. Food and Drug Administration.

[2] "U.S. FDA approves Boehringer's Jascayd (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade". Boehringer Ingelheim (Press release). Retrieved 9 October 2025.

[3] World Health Organization (2024). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 91". WHO Drug Information. 38 (1). hdl: 10665/378096 .

[1]

[2]

[3]